Analytical Data
-
Gene name
OPRL1
- Application
-
Alternative Names
OPRL1; OOR; ORL1; Nociceptin receptor; Kappa-type 3 opioid receptor; KOR-3; Orphanin FQ receptor
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P41146
-
AA Sequence
MEPLFPAPFWEVIYGSHLQGNLSLLSPNHSLLPPHLLLNASHGAFLPLGLKVTIVGLYLAVCVGGLLGNCLVMYVILRHTKMKTATNIYIFNLALADTLVLLTLPFQGTDILLGFWPFGNALCKTVIAIDYYNMFTSTFTLTAMSVDRYVAICHPIRALDVRTSSKAQAVNVAIWALASVVGVPVAIMGSAQVEDEEIECLVEIPTPQDYWGPVFAICIFLFSFIVPVLVISVCYSLMIRRLRGVRLLSGSREKDRNLRRITRLVLVVVAVFVGCWTPVQVFVLAQGLGVQPSSETAVAILRFCTALGYVNSCLNPILYAFLDENFKACFRKFCCASALRRDVQVSDRVRSIAKDVALACKTSETVPRPA
-
Molecular Weight
40.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
OPRL1, or opioid growth factor receptor-like 1, is a G-protein coupled receptor that has gained attention due to its potential roles in various physiological processes and pathologies. Initially identified as a receptor for nociceptin/orphanin FQ, OPRL1 has been implicated in modulating pain, stress responses, and neurodevelopment. Studies have shown that OPRL1 is involved in various signaling pathways, linking it to conditions such as addiction, anxiety, and neurodegenerative diseases. The research into OPRL1 has been focused on understanding its structure, function, and potential as a therapeutic target. Recombinant protein studies have enabled the exploration of OPRL1's molecular interactions and its role in cellular signaling. By producing OPRL1 as a recombinant protein, researchers aim to elucidate the receptor’s binding characteristics, functional assays, and downstream effects on cell signaling. This knowledge may provide insights into the development of new strategies for treating pain and mental health disorders, highlighting the significance of OPRL1 in medical research. As the understanding of OPRL1 deepens, it opens up possibilities for novel drug discovery that could potentially mitigate the side effects associated with traditional opioid therapies and offer alternative therapeutic avenues for conditions related to opioid receptors.
